Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease

Chinese PLA General Hospital (301 Hospital)

Status and phase: Unknown; Phase 4

Conditions: Chronic Kidney Disease

Treatments: Drug: Perindopril; Drug: Valsartan

Study type: Interventional

Funder types: Other

Identifiers

NCT02299310

S2014-088

Details and patient eligibility

About

The purpose of this study is to compare the effect of valsartan and perindopril on HOMA-IR Index in patients with chronic kidney disease.

Full description

eligiable volunteers are administrated single-dose over the period I and II (crossover) of Valsartan (80mg) as of Perindopril (4mg).

Every time before and after each medication, HOMA-IR index and other parameters and safety of Valsartan (80mg) and Perindopril (4mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of chronic kidney disease
• Serum creatinine:1~3mg/dl

Exclusion criteria

• Diabetes
• Patients treated with corticosteroids or immunosuppressants
• BMI>30kg/m2
• SP>180mmHg, DP>110mmHg
• Patients with serious medical problems requiring specific medical treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Valsartan

Experimental group

Description:

Valsartan 80mg/tablet, 1 tablet once daily (crossover)

Treatment:

Drug: Valsartan

Perindopril

Active Comparator group

Description:

Perindopril 4mg/tablet, 1 tablet once daily (crossover)

Treatment:

Drug: Perindopril